Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity.

Elkashef A, Rawson RA, Smith E, Pearce V, Flammino F, Campbell J, Donovick R, Gorodetzky C, Haning W, Mawhinney J, McCann M, Weis D, Williams L, Ling W, Vocci F.

Addiction. 2007 Apr;102 Suppl 1:107-13.

PMID:
17493059
2.

Treatment of methamphetamine use disorders: an update.

Rawson RA, Gonzales R, Brethen P.

J Subst Abuse Treat. 2002 Sep;23(2):145-50. Review.

PMID:
12220612
3.

Treatment of methamphetamine abuse: research findings and clinical directions.

Cretzmeyer M, Sarrazin MV, Huber DL, Block RI, Hall JA.

J Subst Abuse Treat. 2003 Apr;24(3):267-77. Review.

PMID:
12810148
4.
5.
7.

Treatments for methamphetamine abuse: a literature review for the clinician.

Brackins T, Brahm NC, Kissack JC.

J Pharm Pract. 2011 Dec;24(6):541-50. doi: 10.1177/0897190011426557. Epub 2011 Nov 17. Review.

PMID:
22095579
8.

The epidemiology of methamphetamine use and harm in Australia.

Degenhardt L, Roxburgh A, Black E, Bruno R, Campbell G, Kinner S, Fetherston J.

Drug Alcohol Rev. 2008 May;27(3):243-52. doi: 10.1080/09595230801950572. Review.

PMID:
18368605
9.

Approaches to the development of medications for the treatment of methamphetamine dependence.

Vocci FJ, Appel NM.

Addiction. 2007 Apr;102 Suppl 1:96-106. Review.

PMID:
17493058
10.

Methamphetamine abuse.

Winslow BT, Voorhees KI, Pehl KA.

Am Fam Physician. 2007 Oct 15;76(8):1169-74. Review.

11.
12.

A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.

Kollins SH.

Curr Med Res Opin. 2008 May;24(5):1345-57. doi: 10.1185/030079908X280707 . Epub 2008 Apr 1. Review.

PMID:
18384709
13.

Epidemiology of methamphetamine abuse in Missouri.

Topolski JM.

Mo Med. 2007 Jan-Feb;104(1):82-8. Review.

PMID:
17410832
14.

Corticolimbic dysregulation and chronic methamphetamine abuse.

Baicy K, London ED.

Addiction. 2007 Apr;102 Suppl 1:5-15. Review.

PMID:
17493049
15.

Incorporating brain research findings into standard treatment: an example using the Matrix Model.

Obert JL, London ED, Rawson RA.

J Subst Abuse Treat. 2002 Sep;23(2):107-13. Review.

PMID:
12220608
16.

Pharmacological treatments for methamphetamine addiction: current status and future directions.

Ballester J, Valentine G, Sofuoglu M.

Expert Rev Clin Pharmacol. 2017 Mar;10(3):305-314. doi: 10.1080/17512433.2017.1268916. Epub 2016 Dec 20. Review.

PMID:
27927042
17.

Amphetamines: an update on forensic issues.

Logan BK.

J Anal Toxicol. 2001 Jul-Aug;25(5):400-4. Review.

PMID:
11499897
18.

'Tweaking 12-Step': the potential role of 12-Step self-help group involvement in methamphetamine recovery.

Donovan DM, Wells EA.

Addiction. 2007 Apr;102 Suppl 1:121-9. Review.

PMID:
17493061
19.

Involving the pharmaceutical and biotech communities in medication development for substance abuse.

Gorodetzky CW, Grudzinskas C.

Pharmacol Ther. 2005 Oct;108(1):109-18. Review.

PMID:
16038981
20.

Putting the call out for more research: the poor evidence base for treating methamphetamine withdrawal.

Pennay AE, Lee NK.

Drug Alcohol Rev. 2011 Mar;30(2):216-22. doi: 10.1111/j.1465-3362.2010.00240.x. Review.

PMID:
21355922

Supplemental Content

Support Center